Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

First gene therapy nears landmark European market authorization

Nature Biotechnology volume 30, pages 807–808 (2012)Cite this article

Subjects

Approval will also be a watershed moment from a regulatory standpoint, as the EMA's assessment of alipogene has followed protracted deliberations in which the file was examined and voted on four times, and the conventions—if not the rules—governing EMA procedures were thrown out of the window (Box 1).

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. London

    Nuala Moran

Authors
  1. Nuala Moran
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Moran, N. First gene therapy nears landmark European market authorization. Nat Biotechnol 30, 807–808 (2012). https://doi.org/10.1038/nbt0912-807

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0912-807

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research